# Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

> **NCT05278208** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 65 (estimated)

## Conditions studied

- High Grade Glioma
- Meningioma
- Embryonal Tumor
- Medulloblastoma
- Anaplastic Ependymoma
- Recurrent Diffuse Intrinsic Pontine Glioma
- Recurrent Malignant Glioma
- Recurrent Medulloblastoma
- Recurrent Primary Central Nervous System Neoplasm
- Refractory Diffuse Intrinsic Pontine Glioma
- Refractory Malignant Glioma
- Refractory Medulloblastoma
- Refractory Primary Central Nervous System Neoplasm

## Interventions

- **DRUG:** LUTATHERA® (Lutetium Lu 177 dotatate)

## Key facts

- **NCT ID:** NCT05278208
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-21
- **Primary completion:** 2028-11
- **Final completion:** 2033-11
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05278208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05278208, "Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05278208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*